Nov. 29, 2015 biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
Vancouver, BC–(Business Wire)– biOasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis or the “Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (“BBB”), announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company’s Transcend BBB delivery vector. biOasis’ Transcend… Read more »
Nov. 11, 2015 biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies – Inclusive of Trastuzumab – to Treat Her2/neu Brain Metastases
biOasis’ Transcend Platform has shown great utility in pre-clinical animal models to deliver therapeutic compounds into the brain at sufficient levels to reach a therapeutic effect. Without the Transcend delivery vehicle these compounds would otherwise be excluded from the brain due to the presence of the protective blood-brain barrier. The issuance of this patent indicates that compounds, such as in this case Trastuzumab can be, with the help of Transcend, protected under the issuance of a new patent, including for a new therapeutic indication – brain metastases. Trastuzumab coupled to the transport vector Transcend thus offers a potential treatment for this dreadful cancer.
Sep. 29, 2015 biOasis Announces Listing on OTCQB Exchange
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) wishes to announce that its current listing on the OTCQX will be changing to a listing on the OTCQB. The Company’s trading symbol will remain BIOAF. The Company remains in compliance with all relevant TSX Venture and OTCQB reporting standards and will continue trading on… Read more »
Jul. 31, 2015 biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
Vancouver, BC–(Business Wire)– biOasis Technologies, Inc. (OTCQX:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the completion and assessment of the data in the knockout mouse model of Hunter Syndrome (MPS II) performed in Padova, Italy, by a team led by Dr. Maurizio… Read more »
Mar. 17, 2015 biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB carrier peptide (MTfp): MTfp–siRNA Reduces Both the Damage Caused By Infarct and Significantly Improves Neurological Score
– The Ability to Deliver siRNAs to the Brain Represents a Major Potential Advancement for Treatment of CNS Disorders by Modifying Expression of Disease-Causing Genes – Results are announced from a well-established animal ischemic stroke model performed at the National Research Council Canada with the biOasis Transcend carrier peptide, MTfp and siRNA (MTfp–siRNA) – Two KEY therapeutic effects were shown with MTfp–siRNA: High degree of reduction of the area of blood vessel infarct and improvement of overall brain activity as determined by neurological scoring.
Jan. 31, 2015 biOasis Announces Grant of Stock Options
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQX: BIOAF)(the “Company”) wishes to announce that it has granted an aggregate of 1,215,000 incentive stock options (the “Stock Options”) to directors, officers, consultants and employees of the Company pursuant to the Company’s Stock Option Plan, subject to the policies of the TSX Venture Exchange. The Stock Options… Read more »
Jan. 21, 2015 biOasis Announces the Release of an Analyst Report
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQX: BIOAF)(the “Company”) wishes to announce the release of an analyst report (the “Report”) providing a synopsis of the Company. Mr. Jim Darcel, www.jrstocks.com, prepared the Report. The Company cautions its investors, shareholders and other parties that any opinions, estimates or forecasts regarding the Company’s performance made by… Read more »
Oct. 8, 2014 biOasis Engages Willow Tree Group to Assist with Global Business Development Activities
Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc.(OTCQX:BIOAF; TSX.V:BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (“BBB”), engages Willow Tree Capital Group of Toronto, Canada. Willow Tree’s full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies… Read more »
Sep. 19, 2014 biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
One of the most challenging aspects of treating Lysosomal Storage Diseases is the transport of the required enzymes across the Blood-Brain Barrier and into the Central Nervous System.
Sep. 10, 2014 biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
“biOasis initiates pivotal study using a knockout model for Sandhoff Lysosomal Storage Disease”